English

New in-licensing agreement

Report this content
(Lysaker, Norway, 14 March 2008) Navamedic's fully owned subsidiary Vitaflo Scandinavia AB has signed an agreement with Mekos (Denmark) and Smart Practice (Canada) for marketing of the product line Allergeaze in Denmark, Finland, Norway, Sweden and Iceland. This agreement fits well into the Company's strategy to expand the product portfolio in selected knowledge areas.




The current market size for the targeted market is approximately SEK 10 million. The Allergeaze product line is ready to be launched at the marked in Denmark, Finland, Norway, Sweden and Iceland. The agreement has an initial duration of 2 years and may be prolonged for additional 2-year periods.




Tina Madsen Sandström, CEO of Vitaflo Scandinavia, said: I am very pleased with the extension of the cooperation with Mekos as Dermatology is one of our prioritized knowledge areas. With the possibility to offer both a standardised pharmaceutical product for patch testing and now single allergens we will have a very strong position in the Nordic market.




Susanne Munksted sale- and marketing director of Mekos; Vitaflo Scandinavia AB have successfully represented our product TrueTest/MekosTest in the Scandinavian markets since 2004. We value our co-operation and look forward to extending this when including Allergeaze in the portfolio. We are certain that Vitaflo will use best efforts when introducing Allergeaze and look forward to continue our collaboration



For further information, please contact:



Øyvind W. Brekke, CEO Navamedic ASA
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40
Mobile: +47 91 19 81 64



Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA
E-mail: bor@navamedic.com
Office: +47 67 11 25 44
Mobile: +47 91 34 70 21

Subscribe